Introduction to the Belviq Cancer Lawsuit
Belviq Cancer Lawsuit: Began shortly after the U.S Food and Drug Administration’s (FDA) recall of the drug forcing the manufacturer, Eisai Inc., to discontinue sales.
Clinical Trials and Studies: Have linked the drug to increased cancer risk.
You Maybe Be Eligible for a Belviq Lawsuit: If you or a loved one was prescribed Belviq and were diagnosed cancer, you should contact a Belviq cancer lawyer right away.
You may qualify for a Belviq cancer lawsuit and possible entltled to substantial Compensation in a Belviq cancer Lawsuit. Call Belviq cancer lawyer Timothy L. Miles for a free case evaluation today. (855) 846-6529 or [email protected].
Overview of the Belviq Recall
- The Drug: Belviq (lorcaserin) was a prescription weight-loss medication approved by the FDA in 2012 and manufactured by Eisai Inc. and Arena Pharmaceuticals.
- The Risk: A mandatory safety clinical trial involving 12,000 patients showed a higher rate of cancer diagnoses in patients taking Belviq compared to a placebo.
- The Recall: In February 2020, the FDA requested a voluntary withdrawal of Belviq and Belviq XR from the U.S. market after clinical data linked the active ingredient to pancreatic, lung, and colorectal cancers.
Status of the Belviq Cancer Lawsuits
- Belviq Cancer Lawsuits: Belviq Lawsuits claim that the manufacturers downplayed or hid animal-testing cancer risks during the approval process and continued selling a dangerous product.
- Legal Proceedings: Court proceedings have largely been paused or stayed as parties attempted to negotiate settlements, and individual confidential settlements have been reached in select cases.
Qualification Criteria
- Diagnosis: Individuals diagnosed with pancreatic, lung, colorectal, or breast cancer after using Belviq.
- Usage History: Typically required to have taken the medication for a significant duration (often six months or more) within a specific timeframe prior to the cancer diagnosis.

What is Belviq and How Does it Work?
- Belviq (lorcaserin): Is a popular prescription weight-loss drug. The drug is sold and produced by Eisai Inc., a Tokyo-based drugmaker.
- Initial Approval: Belviq was initially approved by the FDA in 2012 for U.S. markets. Belviq alters the brain’s chemical signals responsible for appetite and increases feelings of fullness to help patients lose weight.
- Treaatmentn to Lose Weight: The drug is used as a combined treatment with diet and exercise to help adults who are overweight, obese, or suffering weight-related medical problems.
- Obesity Linked to Diabetes: Belviq is sometimes prescribed to treat obesity linked to diabetes, high blood pressure, and high cholesterol, but it does not treat underlying health conditions.
What’s The Difference Between Belviq and Belviq XR?
- Belviq (lorcaserin) was available in two separate forms.
- Belviq is a 10 mg tablet prescribed to be taken twice a day.
- Belviq XR is an extended-release form of lorcaserin prescribed as one daily dose.
Is Belviq Dangerous?
- The FDA requested that Eisai Inc. withdraw Belviq from U.S. markets citing concerns over the drug’s ties to cancer. Since Belviq was approved in 2012, researchers have been studying the medication’s safety.
- The FDA originally required that the drug manufacturer conduct a double-blind, randomized, placebo-controlled clinical trial that tested for risks of heart-related health problems.
- The researchers analyzed approximately 12,000 participants, some of who were given Belviq while some took a placebo.
- Researchers did not discover subsequent heart problems tied to Belviq, but they did find that patients taking the drug had a higher cancer diagnosis rate than those who took a placebo.
The Link Between Belviq and Cancer
FDA Reaearch: FDA researchers discovered increased rates of cancer in patients prescribed Belviq. About 7.7 percent of patients who took Belviq had a cancer diagnosis compared to 7.1 percent who received a placebo.
Cancer Diagnosis: Over the course of the trial, 662 Belviq patients were diagnosed with 520 primary cancers while the placebo group had 423 patients diagnosed with 470 cancers.The FDA also reported that the longer a patient was on Belviq, the greater the increased risk of developing cancer.
Early Studies: Early studies performed on rats also hinted that Belviq might cause cancer. Prior to the drug’s approval in 2012, manufacturer testing linked Belviq to an increased rate of cancerous tumors in rats.
FDA Withdrawal: The FDA was concerned with the findings, but the risks were not deemed significant enough to pull Belviq from markets. The FDA has reversed its stance following the 2020 research that showed definitive evidence linking Belviq and cancer.
Does Belviq Cause Cancer?
- The FDA announced in January that clinical trial results tied Belviq and Belviq XR to a possible increased risk of cancer. The agency said that the drug’s cancer risks were significant enough to call for the drug to be removed from the U.S. market.
- The agency notes that they cannot conclude that Belviq and Belviq XR contribute to the cancer risks, and the cause of developed cancers is still uncertain.However, the agency noted that the risks of the medicine outweigh its benefits and recommend people using Belviq for weight loss stop taking the drug immediately.

Types of Cancers Linked to Belviq
The FDA requested the recall of Belviq and Belviq XR because of increased rates of cancers tied to the drug.
The agency reported several different types of belviq cancers including:
Belviq Pancreatic Cancer
Studies reveal Belviq causes an increased risk of Belviq Pancreatic cancer.
Belviq Colon Cancer
Studies reveal Belviq causes an increased risk of colorectal cancer.
Belviq Lung Cancer
Studies reveal Belviq causes an increased risk of lung cancer.
Other Belviq Cancers
Researchers are studying the possible Belviq links to increased risks of other cancers, including breast cancer and brain cancer.
Belviq Adverse Effects
The FDA recommended that people taking Belviq or Belviq XR immediately stop taking the drug following research findings tying the medication to increased cancer risks.
The medication also presents numerous other risks and side effects.
It is important to note that the drug was only approved for people who are obese (with a body-mass index of 30 or more) or overweight (with a BMI between 27 and 30) and have high blood pressure, high cholesterol, or diabetes.
Belviq side effects include:
- Headaches
- Dizziness
- Fatigue
- Nausea
- Dry Mouth
- Constipation
Has Belviq Been Recalled?
- Belviq Recall: Yes, Belviq has been recalled. The (FDA) requested the weight-loss drug Belviq be pulled from U.S. markets in February after safety clinical trials tied the medication to increased rates of cancer.
- Voluntart Removed from Market: Eisai Inc., the Tokyo-based manufacturer of the drug, submitted voluntary requests to withdraw the drug from the market.
FDA Recommendations For Belviq Patients
FDA officials recommended that people taking Belviq stop immediately. Patients should talk to a health care provider to find alternative weight-loss drugs and weight management programs.
Belviq should be disposed of at a drug take-back location, or in household trash using the following four (4) steps:
- Mix the medication with an uninviting substance such as dirt, used coffee grounds, or cat litter. Do not crush the pills.
- Place the mixture in a sealed container such as a plastic bag or bottle.
- Throw the container away in your household trash.
- Remove all personal information from the prescription labels on empty medication bottles or packaging. Recycle or throw away the containers.
The agency is not recommending special cancer screening for patients who took Belviq.
Do I Qualify for a Belviq Cancer Lawsuit?
Patients may be eligible for a Belviq lawsuit if they took:
- Belviq
- Belviq XR
And were subsequently diagnosed with:
- Pancreatic cancer
- Or other cancers
If you believe you may qualify for a Belviq Cancer Lawsuit, contact Belviq cancer lawyer Timothy L. Miles for a free case evaluation today.
Gathering Evidence for a Belviq Cancer Lawsuit
Potential evidence in a Dacthal Exposure Lawsuit may include:
- Medical Records: Documentation of cancer diagnosis, including diagnoses, treatments, and any related medical expenses.
- Exposure History: Detailed records of when, where, and how you were exposed to Dacthal, such as employment records, residence history, or agricultural activities.
- Environmental Testing Results: Evidence of DCPA contamination in your environment, such as soil, water, or air quality tests, particularly near agricultural or non-agricultural areas where Dacthal was used.
- Expert Testimony: Statements from medical experts, toxicologists, or environmental scientists that link your health issues to DCPA exposure.
- Witness Statements: Testimonies from coworkers, neighbors, or others who can confirm your exposure to Dacthal and any resulting health effects.
- Product Labels and Warnings: Documentation of the Dacthal product labels, usage instructions, and any warnings provided by the manufacturer, especially if they were inadequate or misleading.
- Regulatory Documents: EPA reports, safety assessments, and other government documents that outline the risks associated with DCPA and the actions taken by regulatory bodies.
Contact Belviq Cancer Lawwer Timothy L. Miles Today for a Free Case Evaluation
If you or a loved one were injured by a Belviq, call, you may qualify for a Belviq cancer lawsuit and possible entltled to substantial compensation in a Belviq cancer Lawsuit. Call Belviq cancer lawyer Timothy L. Miles for a free case evaluation today.
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com
Facebook Linkedin Pinterest youtube
